Literature DB >> 27421740

Improving efficacy of cancer immunotherapy by genetic modification of natural killer cells.

Rachel A Burga1, Tuongvan Nguyen2, Jane Zulovich2, Sarah Madonna2, Loyda Ylisastigui2, Rohan Fernandes1, Eric Yvon3.   

Abstract

Natural killer (NK) cells are members of the innate immune system that recognize target cells via activating and inhibitory signals received through cell receptors. Derived from the lymphoid lineage, NK cells are able to produce cytokines and exert a cytotoxic effect on viral infected and malignant cells. It is their unique ability to lyse target cells rapidly and without prior education that renders NK cells a promising effector cell for adoptive cell therapy. However, both viruses and tumors employ evasion strategies to avoid attack by NK cells, which represent biological challenges that need to be harnessed to fully exploit the cytolytic potential of NK cells. Using genetic modification, the function of NK cells can be enhanced to improve their homing, cytolytic activity, in vivo persistence and safety. Examples include gene modification to express chemokine, high-affinity Fc receptor and chimeric antigen receptors, suicide genes and the forced expression of cytokines such as interleukin (IL)-2 and IL-15. Preclinical studies have clearly demonstrated that such approaches are effective in improving NK-cell function, homing and safety. In this review, we summarize the recent advances in the genetic manipulations of NK cells and their application for cellular immunotherapeutic strategies.
Copyright © 2016 International Society for Cellular Therapy. Published by Elsevier Inc. All rights reserved.

Entities:  

Keywords:  gene transfer; immunotherapy; natural killer cells

Mesh:

Year:  2016        PMID: 27421740     DOI: 10.1016/j.jcyt.2016.05.018

Source DB:  PubMed          Journal:  Cytotherapy        ISSN: 1465-3249            Impact factor:   5.414


  13 in total

1.  Natural killer-like signature observed post therapy in locally advanced rectal cancer is a determinant of pathological response and improved survival.

Authors:  Matthew Alderdice; Philip D Dunne; Aidan J Cole; Paul G O'Reilly; Darragh G McArt; Vicky Bingham; Marc-Aurel Fuchs; Stephen McQuaid; Maurice B Loughrey; Graeme I Murray; Leslie M Samuel; Mark Lawler; Richard H Wilson; Manuel Salto-Tellez; Vicky M Coyle
Journal:  Mod Pathol       Date:  2017-06-16       Impact factor: 7.842

Review 2.  Natural killer cells in inflammatory heart disease.

Authors:  SuFey Ong; Noel R Rose; Daniela Čiháková
Journal:  Clin Immunol       Date:  2016-11-25       Impact factor: 3.969

Review 3.  CAR T-cells for T-cell malignancies: challenges in distinguishing between therapeutic, normal, and neoplastic T-cells.

Authors:  Marion Alcantara; Melania Tesio; Carl H June; Roch Houot
Journal:  Leukemia       Date:  2018-10-12       Impact factor: 11.528

4.  Efficacy of third-party chimeric antigen receptor modified peripheral blood natural killer cells for adoptive cell therapy of B-cell precursor acute lymphoblastic leukemia.

Authors:  C Quintarelli; S Sivori; S Caruso; S Carlomagno; L Moretta; F Locatelli; M Falco; I Boffa; D Orlando; M Guercio; Z Abbaszadeh; M Sinibaldi; S Di Cecca; A Camera; B Cembrola; A Pitisci; M Andreani; L Vinti; S Gattari; F Del Bufalo; M Algeri; G Li Pira; A Moseley; B De Angelis
Journal:  Leukemia       Date:  2019-11-19       Impact factor: 11.528

Review 5.  Targeting TDO in cancer immunotherapy.

Authors:  Cheng-Peng Yu; Yun-Lei Song; Zheng-Ming Zhu; Bo Huang; Ying-Qun Xiao; Da-Ya Luo
Journal:  Med Oncol       Date:  2017-03-29       Impact factor: 3.064

Review 6.  Next generation natural killer cells for cancer immunotherapy: the promise of genetic engineering.

Authors:  May Daher; Katayoun Rezvani
Journal:  Curr Opin Immunol       Date:  2018-03-30       Impact factor: 7.486

Review 7.  Dysregulation of Chemokine/Chemokine Receptor Axes and NK Cell Tissue Localization during Diseases.

Authors:  Giovanni Bernardini; Fabrizio Antonangeli; Valentina Bonanni; Angela Santoni
Journal:  Front Immunol       Date:  2016-10-06       Impact factor: 7.561

Review 8.  Redirected Primary Human Chimeric Antigen Receptor Natural Killer Cells As an "Off-the-Shelf Immunotherapy" for Improvement in Cancer Treatment.

Authors:  Olaf Oberschmidt; Stephan Kloess; Ulrike Koehl
Journal:  Front Immunol       Date:  2017-06-09       Impact factor: 7.561

9.  Ex vivo-expanded highly purified natural killer cells in combination with temozolomide induce antitumor effects in human glioblastoma cells in vitro.

Authors:  Yoshitaka Tanaka; Tsutomu Nakazawa; Mitsutoshi Nakamura; Fumihiko Nishimura; Ryosuke Matsuda; Koji Omoto; Yoichi Shida; Toshiharu Murakami; Ichiro Nakagawa; Yasushi Motoyama; Hiromichi Morita; Takahiro Tsujimura; Hiroyuki Nakase
Journal:  PLoS One       Date:  2019-03-06       Impact factor: 3.240

10.  Hit-and-run programming of therapeutic cytoreagents using mRNA nanocarriers.

Authors:  H F Moffett; M E Coon; S Radtke; S B Stephan; L McKnight; A Lambert; B L Stoddard; H P Kiem; M T Stephan
Journal:  Nat Commun       Date:  2017-08-30       Impact factor: 14.919

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.